

Laura A Magee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3044381/publications.pdf>

Version: 2024-02-01

153
papers

16,440
citations

36691

53
h-index

19470

122
g-index

160
all docs

160
docs citations

160
times ranked

14103
citing authors

#	ARTICLE	IF	CITATIONS
1	Navigating uncertainty alone: A grounded theory analysis of women's psycho-social experiences of pregnancy and childbirth during the COVID-19 pandemic in London. <i>Women and Birth</i> , 2023, 36, e106-e117.	0.9	8
2	Toward personalized management of chronic hypertension in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, S1196-S1210.	0.7	16
3	Guidelines' similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, S1222-S1236.	0.7	69
4	An internally validated prediction model for critical COVID-19 infection and intensive care unit admission in symptomatic pregnant women. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 403.e1-403.e13.	0.7	23
5	The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. <i>Pregnancy Hypertension</i> , 2022, 27, 148-169.	0.6	189
6	Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses. <i>Hypertension</i> , 2022, 79, 614-628.	1.3	21
7	How Gender Influenced the Experience of Using a mHealth Intervention in Rural Mozambique: Secondary Qualitative Analysis of Community Health Worker Survey Data. <i>Frontiers in Global Women S Health</i> , 2022, 3, 661000.	1.1	0
8	COVID-19 booster doses in pregnancy and global vaccine equity. <i>Lancet</i> , The, 2022, 399, 907-908.	6.3	13
9	Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 294.e1-294.e11.	0.7	5
10	Clinical severity of <sc>SARS-CoV-2 infection among vaccinated and unvaccinated pregnancies during the Omicron wave. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 560-562.	0.9	30
11	Diagnosis and Monitoring of White Coat Hypertension in Pregnancy: an ISSHP Consensus Delphi Procedure. <i>Hypertension</i> , 2022, 79, 993-1005.	1.3	4
12	Maternal and perinatal outcomes of <sc>SARS-CoV-2 infection in unvaccinated pregnancies during Delta and Omicron waves. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 60, 96-102.	0.9	38
13	Re: Reducing health inequality in Black, Asian and other minority ethnic pregnant women: Impact of first-trimester combined screening for placental dysfunction on perinatal mortality. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, , .	1.1	0
14	Preeclampsia. <i>New England Journal of Medicine</i> , 2022, 386, 1817-1832.	13.9	150
15	Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2022, 44, 547-571.e1.	0.3	60
16	Directive clinique no 426 : Troubles hypertensifs de la grossesse : Diagnostic, prÃ©diction, prÃ©vention et Ã©prise en charge. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2022, 44, 572-597.e1.	0.3	0
17	Anemia and adverse outcomes in pregnancy: subgroup analysis of the CLIP cluster-randomized trial in India. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, 407.	0.9	3
18	Calcium for pre-eclampsia prevention: A systematic review and network meta-analysis to guide personalised antenatal care. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1833-1843.	1.1	25

#	ARTICLE	IF	CITATIONS
19	On race and ethnicity during a global pandemic: An “imperfect mosaic”™ of maternal and child health services in ethnically-diverse South London, United Kingdom. <i>EClinicalMedicine</i> , 2022, 48, 101433.	3.2	12
20	Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 518.e1-518.e11.	0.7	38
21	Maternity services in the UK during the coronavirus disease 2019 pandemic: a national survey of modifications to standard care. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 880-889.	1.1	125
22	The impact of pre-eclampsia definitions on the identification of adverse outcome risk in hypertensive pregnancy “analyses from the CHIPS trial (Control of Hypertension in Pregnancy Study). <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1373-1382.	1.1	9
23	Effect of COVID-19 on maternal and neonatal services. <i>The Lancet Global Health</i> , 2021, 9, e112.	2.9	8
24	The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: A randomized placebo-controlled study. <i>Pregnancy Hypertension</i> , 2021, 23, 91-96.	0.6	7
25	Can risk prediction models help us individualise stillbirth prevention? A systematic review and critical appraisal of published risk models. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 214-224.	1.1	15
26	Genomic imbalances in the placenta are associated with poor fetal growth. <i>Molecular Medicine</i> , 2021, 27, 3.	1.9	13
27	Authors' reply re: Maternity services in the UK during the coronavirus disease 2019 pandemic: a national survey of modifications to standard care. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 937-938.	1.1	4
28	“Now You Have Become Doctors”: Lady Health Workers' Experiences Implementing an mHealth Application in Rural Pakistan. <i>Frontiers in Global Women S Health</i> , 2021, 2, 645705.	1.1	3
29	Maternal Dietary Patterns and Pregnancy Hypertension in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. <i>Advances in Nutrition</i> , 2021, 12, 2387-2400.	2.9	13
30	Implementation of the PIERS on the Move mHealth Application From the Perspective of Community Health Workers and Nurses in Rural Mozambique. <i>Frontiers in Global Women S Health</i> , 2021, 2, 659582.	1.1	4
31	The ability and safety of community-based health workers to safely initiate lifesaving therapies for pre-eclampsia in Ogun State, Nigeria: An analysis of 260 community treatments with MgSO4 and/or methyldopa. <i>Pregnancy Hypertension</i> , 2021, 25, 179-184.	0.6	2
32	Economic and cost-effectiveness analysis of the Community-Level Interventions for Pre-eclampsia (CLIP) trials in India, Pakistan and Mozambique. <i>BMJ Global Health</i> , 2021, 6, e004123.	2.0	4
33	Pregnancy Outcomes and Blood Pressure Visit-to-Visit Variability and Level in Three Less-Developed Countries. <i>Hypertension</i> , 2021, 77, 1714-1722.	1.3	4
34	Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2021, 9, e759-e772.	2.9	645
35	A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 154, 3-31.	1.0	34
36	Global changes in maternity care provision during the COVID-19 pandemic: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 37, 100947.	3.2	92

#	ARTICLE	IF	CITATIONS
37	Blood pressure thresholds in pregnancy for identifying maternal and infant risk: a secondary analysis of Community-Level Interventions for Pre-eclampsia (CLIP) trial data. <i>The Lancet Global Health</i> , 2021, 9, e1119-e1128.	2.9	10
38	SARS-CoV-2 vaccination in pregnancy: a unique opportunity for equity. <i>Lancet, The</i> , 2021, 398, 951.	6.3	10
39	Causes and circumstances of maternal death: a secondary analysis of the Community-Level Interventions for Pre-eclampsia (CLIP) trials cohort. <i>The Lancet Global Health</i> , 2021, 9, e1242-e1251.	2.9	14
40	Community Health Worker Evaluation of Implementing an mHealth Application to Support Maternal Health Care in Rural India. <i>Frontiers in Global Women S Health</i> , 2021, 2, 645690.	1.1	8
41	Women's experiences of maternity service reconfiguration during the COVID-19 pandemic: A qualitative investigation. <i>Midwifery</i> , 2021, 102, 103116.	1.0	50
42	Refreshing our magnesium sulphate strategy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, , .	1.1	0
43	Community-level interventions for pre-eclampsia (CLIP) in Pakistan: A cluster randomised controlled trial. <i>Pregnancy Hypertension</i> , 2020, 22, 109-118.	0.6	26
44	Research priorities for pregnancy hypertension: a UK priority setting partnership with the James Lind Alliance. <i>BMJ Open</i> , 2020, 10, e036347.	0.8	11
45	Interactions between the Physical and Social Environments with Adverse Pregnancy Events Related to Placental Disordersâ€”A Scoping Review. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5421.	1.2	4
46	The Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised trials in Mozambique, Pakistan, and India: an individual participant-level meta-analysis. <i>Lancet, The</i> , 2020, 396, 553-563.	6.3	28
47	The PRECISE (PREgnancy Care Integrating translational Science, Everywhere) database: open-access data collection in maternal and newborn health. <i>Reproductive Health</i> , 2020, 17, 50.	1.2	7
48	Hypertension Canadaâ€™s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020, 36, 596-624.	0.8	324
49	A core outcome set for pre-eclampsia research: an international consensus development study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1516-1526.	1.1	68
50	Patient Preferences and Decisional Needs When Choosing a Treatment Approach for Pregnancy Hypertension: A Stated Preference Study. <i>Canadian Journal of Cardiology</i> , 2020, 36, 775-779.	0.8	11
51	Community-level interventions for pre-eclampsia (CLIP) in Mozambique: A cluster randomised controlled trial. <i>Pregnancy Hypertension</i> , 2020, 21, 96-105.	0.6	23
52	Community level interventions for pre-eclampsia (CLIP) in India: A cluster randomised controlled trial. <i>Pregnancy Hypertension</i> , 2020, 21, 166-175.	0.6	28
53	Pregnancy hypertension diagnosis and care in COVID-19 era and beyond. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 56, 7-10.	0.9	13
54	SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes. <i>EclinicalMedicine</i> , 2020, 25, 100446.	3.2	250

#	ARTICLE	IF	CITATIONS
55	Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2020, 324, 705.	3.8	377
56	Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data. Pregnancy Hypertension, 2020, 19, 87-93.	0.6	11
57	Population-level data on antenatal screening for proteinuria; India, Mozambique, Nigeria, Pakistan. Bulletin of the World Health Organization, 2020, 98, 661-670.	1.5	3
58	Placental growth factor as an indicator of fetal growth restriction in late-onset small-for-gestational age pregnancies. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 89-95.	0.4	12
59	Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet, The, 2019, 394, 1011-1021.	6.3	89
60	Management of non-severe pregnancy hypertension – A summary of the CHIPS Trial (Control of Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.6	17
61	A prediction model for short-term neonatal outcomes in severe early-onset fetal growth restriction. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 241, 109-118.	0.5	26
62	Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 330-339.	6.3	90
63	Self-reported maternal morbidity: Results from the community level interventions for pre-eclampsia (CLIP) baseline survey in Sindh, Pakistan. Pregnancy Hypertension, 2019, 17, 113-120.	0.6	6
64	Place-specific factors associated with adverse maternal and perinatal outcomes in Southern Mozambique: a retrospective cohort study. BMJ Open, 2019, 9, e024042.	0.8	8
65	Preface: Renal disease in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2019, , .	1.4	0
66	The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis. PLoS Medicine, 2019, 16, e1002783.	3.9	72
67	Hypertension Canada's 2018 Guidelines for the Management of Hypertension in Pregnancy. Canadian Journal of Cardiology, 2018, 34, 526-531.	0.8	164
68	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
69	Influence of Gestational Age at Initiation of Antihypertensive Therapy. Hypertension, 2018, 71, 1170-1177.	1.3	25
70	TEMPORARY REMOVAL: The hypertensive disorders of pregnancy: ISSHP classification, diagnosis and management recommendations for international practice 2018.. Pregnancy Hypertension, 2018, , .	0.6	4
71	Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique. Pregnancy Hypertension, 2018, 11, 26-31.	0.6	12
72	MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP) – implementation of a national guideline in Canada. Implementation Science, 2018, 13, 8.	2.5	28

#	ARTICLE	IF	CITATIONS
73	Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. <i>Pregnancy Hypertension</i> , 2018, 11, 115-123.	0.6	79
74	State-of-the-Art Diagnosis and Treatment of Hypertension in Pregnancy. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1664-1677.	1.4	40
75	Characterization of maternal plasma biomarkers associated with delivery of small and large for gestational age infants in the MIREC study cohort. <i>PLoS ONE</i> , 2018, 13, e0204863.	1.1	12
76	CHIPS-Child: Testing the developmental programming hypothesis in the offspring of the CHIPS trial. <i>Pregnancy Hypertension</i> , 2018, 14, 15-22.	0.6	4
77	The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. <i>Pregnancy Hypertension</i> , 2018, 13, 291-310.	0.6	719
78	Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial. <i>Pregnancy Hypertension</i> , 2018, 13, 121-126.	0.6	5
79	Hypertensive Disorders of Pregnancy. <i>Hypertension</i> , 2018, 72, 24-43.	1.3	1,200
80	Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique. <i>Hypertension</i> , 2017, 69, 469-474.	1.3	20
81	Visual or automated dipstick testing for proteinuria in pregnancy?. <i>Pregnancy Hypertension</i> , 2017, 7, 50-53.	0.6	11
82	Seasonal variation in geographical access to maternal health services in regions of southern Mozambique. <i>International Journal of Health Geographics</i> , 2017, 16, 1.	1.2	97
83	Reverse innovation in maternal health. <i>Obstetric Medicine</i> , 2017, 10, 113-119.	0.5	5
84	Massive Urinary Protein Excretion Associated with Greater Neonatal Risk in Preeclampsia. <i>AJP Reports</i> , 2017, 07, e49-e58.	0.4	27
85	Timing of delivery in a high-risk obstetric population: a clinical prediction model. <i>BMC Pregnancy and Childbirth</i> , 2017, 17, 202.	0.9	10
86	Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. <i>BMC Medicine</i> , 2017, 15, 68.	2.3	40
87	Determinants of magnesium sulphate use in women hospitalized at ≥ 29 weeks with severe or non-severe pre-eclampsia. <i>PLoS ONE</i> , 2017, 12, e0189966.	1.1	5
88	Editorial. <i>Obstetric Medicine</i> , 2017, 10, 3-4.	0.5	0
89	Preventing deaths due to the hypertensive disorders of pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2016, 36, 83-102.	1.4	102
90	Oral nifedipine or intravenous labetalol for severe hypertension?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 48-48.	1.1	3

#	ARTICLE	IF	CITATIONS
91	Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 1143-1151.	1.1	63
92	Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. <i>Placenta</i> , 2016, 42, 1-8.	0.7	159
93	Women's views and postpartum follow-up in the CHIPS Trial (Control of Hypertension in Pregnancy) Tj ETQq1 1 0.784314 rgBT /Over 0.5	0.5	17
94	The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). <i>Hypertension</i> , 2016, 68, 1049-1055.	1.3	10
95	The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study). <i>Hypertension</i> , 2016, 68, 1153-1159.	1.3	171
96	Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 763-776.	1.3	10
97	Obstetric medical care in Canada. <i>Obstetric Medicine</i> , 2016, 9, 117-119.	0.5	11
98	Control of Hypertension In Pregnancy Study randomised controlled trial—are the results dependent on the choice of labetalol or methyldopa?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 1135-1141.	1.1	17
99	Pre-eclampsia. <i>Lancet, The</i> , 2016, 387, 999-1011.	6.3	1,262
100	Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. <i>BMC Pregnancy and Childbirth</i> , 2015, 15, 347.	0.9	6
101	Assessing the Incremental Value of Blood Oxygen Saturation (SpO2) in the miniPIERS (Pre-eclampsia) Tj ETQq1 1 0.784314 rgBT /Over 0.3 27 2015, 37, 16-24.	0.3	27
102	Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2015, 37, 975-987.	0.3	9
103	Global obstetric medicine: Collaborating towards global progress in maternal health. <i>Obstetric Medicine</i> , 2015, 8, 138-145.	0.5	11
104	Less-Tight versus Tight Control of Hypertension in Pregnancy. <i>New England Journal of Medicine</i> , 2015, 372, 407-417.	13.9	516
105	Usability and Feasibility of PIERS on the Move: An mHealth App for Pre-Eclampsia Triage. <i>JMIR MHealth and UHealth</i> , 2015, 3, e37.	1.8	61
106	Hypertensive Disorders of Pregnancy: A Systematic Review of International Clinical Practice Guidelines. <i>PLoS ONE</i> , 2014, 9, e113715.	1.1	156
107	A Risk Prediction Model for the Assessment and Triage of Women with Hypertensive Disorders of Pregnancy in Low-Resourced Settings: The miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Multi-country Prospective Cohort Study. <i>PLoS Medicine</i> , 2014, 11, e1001589.	3.9	152
108	Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2014, 36, 416-438.	0.3	441

#	ARTICLE	IF	CITATIONS
109	Development of mHealth Applications for Pre-Eclampsia Triage. IEEE Journal of Biomedical and Health Informatics, 2014, 18, 1857-1864.	3.9	71
110	Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertension, 2014, 4, 105-145.	0.6	303
111	Hypertensive disorders of pregnancy and the recent increase in obstetric acute renal failure in Canada: population based retrospective cohort study. BMJ, The, 2014, 349, g4731-g4731.	3.0	77
112	Pre-eclampsia: An Update. Current Hypertension Reports, 2014, 16, 454.	1.5	90
113	Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 1210-1218.	1.1	80
114	Uric Acid as a Predictor of Adverse Maternal and Perinatal Outcomes in Women Hospitalized With Preeclampsia. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 870-877.	0.3	42
115	In Response. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 575-576.	0.3	129
116	Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 113-118.	1.1	35
117	Pharmacotherapy for Preeclampsia in Low and Middle Income Countries: An Analysis of Essential Medicines Lists. Journal of Obstetrics and Gynaecology Canada, 2013, 35, 215-223.	0.3	17
118	Redefining Preeclampsia Using Placenta-Derived Biomarkers. Hypertension, 2013, 61, 932-942.	1.3	308
119	Acute myocardial infarction in the obstetric patient. Obstetric Medicine, 2012, 5, 50-57.	0.5	4
120	Reversed umbilical arterial end diastolic flow, sildenafil treatment and early stillbirths. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 510-510.	1.1	0
121	Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?. American Journal of Obstetrics and Gynecology, 2012, 206, 163.e1-163.e7.	0.7	91
122	Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet, The, 2011, 377, 219-227.	6.3	431
123	PIERS Proteinuria: Relationship With Adverse Maternal and Perinatal Outcome. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 588-597.	0.3	49
124	The Canadian Perinatal Network: A National Network Focused on Threatened Preterm Birth at 22 to 28 Weeks™ Gestation. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 111-120.	0.3	10
125	Optimal timing of delivery in pregnancies with pre-existing hypertension. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 49-54.	1.1	49
126	Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 624-628.	1.1	151

#	ARTICLE	IF	CITATIONS
127	Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 469.e1-469.e8.	0.7	73
128	Therapeutics and anaesthesia. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2011, 25, 477-490.	1.4	3
129	Choosing outcomes in pregnancy research. <i>Obstetric Medicine</i> , 2011, 4, 131-132.	0.5	0
130	Identifying potentially eligible subjects for research: paper-based logs versus the hospital administrative database. <i>Chronic Diseases and Injuries in Canada</i> , 2011, 32, 43-6.	1.4	0
131	Identifying potentially eligible subjects for research: paper-based logs versus the hospital administrative database. <i>Chronic Diseases and Injuries in Canada</i> , 2011, 32, 43-46.	1.4	0
132	Pre-eclampsia. <i>Lancet, The</i> , 2010, 376, 631-644.	6.3	2,648
133	What is SNOMED CT® and Why Should the ISSHP Care?. <i>Hypertension in Pregnancy</i> , 2009, 28, 119-121.	0.5	4
134	Expectant Management of Severe Preeclampsia Remote from Term: A Structured Systematic Review. <i>Hypertension in Pregnancy</i> , 2009, 28, 312-347.	0.5	88
135	The 24-hour urine collection: gold standard or historical practice?. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 625.e1-625.e6.	0.7	126
136	Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. <i>BMJ: British Medical Journal</i> , 2008, 336, 1003-1006.	2.4	195
137	PRE-ECLAMPSIA AS A MARKER OF CARDIOVASCULAR DISEASE. <i>Fetal and Maternal Medicine Review</i> , 2008, 19, 271-292.	0.3	1
138	Albumin:creatinine ratio using an automated analyser was accurate for diagnosing proteinuria in pregnancy. <i>Evidence-Based Medicine</i> , 2008, 13, 119-119.	0.6	0
139	RETIRED: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2008, 30, S1-S2.	0.3	372
140	Women's Views of Their Experiences in the CHIPS (Control of Hypertension in Pregnancy Study) Pilot Trial. <i>Hypertension in Pregnancy</i> , 2007, 26, 371-387.	0.5	38
141	The Control of Hypertension In Pregnancy Study pilot trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007, 114, 770-e20.	1.1	75
142	DIAGNOSIS AND MANAGEMENT OF NAUSEA AND VOMITING IN PREGNANCY. <i>Fetal and Maternal Medicine Review</i> , 2006, 17, 45-67.	0.3	4
143	THE PRACTICALITIES OF MANAGING SEIZURES IN PREGNANCY: A REVIEW. <i>Fetal and Maternal Medicine Review</i> , 2004, 15, 181-204.	0.3	0
144	Do Commonly Used Oral Antihypertensives Alter Fetal or Neonatal Heart Rate Characteristics? A Systematic Review. <i>Hypertension in Pregnancy</i> , 2004, 23, 155-169.	0.5	55

#	ARTICLE	IF	CITATIONS
145	Serious Perinatal Complications of Non-Proteinuric Hypertension: An International, Multicentre, Retrospective Cohort Study. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2003, 25, 372-382.	0.3	53
146	Fall in Mean Arterial Pressure and Fetal Growth Restriction in Pregnancy Hypertension: An Updated Metaregression Analysis. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2002, 24, 941-945.	0.3	111
147	Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, S256-S261.	0.7	181
148	Development of a health-related quality of life instrument for nausea and vomiting of pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, S232-S238.	0.7	67
149	Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. <i>Lancet</i> , The, 2000, 355, 87-92.	6.3	460
150	A Risk-Benefit Assessment of Pharmacological and Nonpharmacological Treatments for Nausea and Vomiting of Pregnancy. <i>Drugs</i> , 2000, 59, 781-800.	4.9	127
151	The perception of teratogenic risk by women with nausea and vomiting of pregnancy. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 200-200.	2.3	0
152	Management of hypertension in pregnancy. <i>BMJ: British Medical Journal</i> , 1999, 318, 1332-1336.	2.4	281
153	Safety of first trimester exposure to histamine H2 blockers. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1145-1149.	1.1	66